23:21 , Mar 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis B virus (HBV) Patient sample and mouse studies suggest agonizing OX40 could help treat HBV infection in patient subsets with poor viral clearance, including pediatric patients with acute infection and adults with chronic...
17:24 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

Inovio reports interim Phase I data for HBV candidate

Inovio Pharmaceuticals Inc. (NASDAQ:INO) reported interim data from a Phase I trial showing that HBV candidate INO-1800 was well tolerated and generated virus-specific T cells, including CD8+ killer T cells. The open-label, dose-escalation, international trial enrolled...
23:35 , Feb 1, 2018 |  BC Innovations  |  Translation in Brief

Cloning closer to home

Chinese Academy of Sciences researchers showed epigenetic modification is key for successful cloning of cynomolgus monkeys, overcoming the technical hurdles that have stalled the generation of live non-human primates despite success in 23 other mammalian...
16:40 , Jan 10, 2018 |  BC Week In Review  |  Company News

Dynavax launches Heplisav-B in the U.S.

Dynavax Technologies Corp. (NASDAQ:DVAX) launched Heplisav-B in the U.S. to prevent infection caused by all known subtypes of HBV in adults. Heplisav-B combines hepatitis B surface antigen (HBsAg) with a toll-like receptor 9 (TLR9) agonist....
01:20 , Jan 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis B virus (HBV) Mouse studies suggest promoting the expression of IL-21 or IL-33 could help treat HBV infection. In two mouse models of HBV, IV injection of plasmids encoding IL-21 or IL-33 decreased levels...
19:12 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

VBI starts Phase III of Sci-B-Vac to prevent HBV infection

VBI Vaccines Inc. (NASDAQ:VBIV) began the double-blind, international Phase III PROTECT trial of Sci-B-Vac to prevent HBV infection in about 1,600 adults. Subjects will receive a three-dose course of 10 μg Sci-B-Vac or Engerix-B from GlaxoSmithKline...
19:11 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

VBI starts Phase III lot consistency trial of HBV vaccine

VBI Vaccines Inc. (NASDAQ:VBIV) began the double-blind, international Phase III CONSTANT trial to evaluate lot-to-lot consistency of Sci-B-Vac to prevent HBV infection. The study will enroll 3,200 adults to receive a three-dose course from one of...
21:38 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Arbutus' ARB-1467 leads to HBsAg responses in Phase IIa for HBV infection

Arbutus Biopharma Corp. (NASDAQ:ABUS) reported data from 11 evaluable hepatitis B e antigen (HBeAg)-negative patients with chronic HBV infection in cohort 4 of the Phase IIa ARB-1467-002 trial showing that 0.4 mg/kg IV ARB-1467 every...
20:44 , Nov 10, 2017 |  BC Week In Review  |  Clinical News

FDA approves Dynavax's HBV vaccine

FDA approved Heplisav-B from Dynavax Technologies Corp. (NASDAQ:DVAX) to prevent infection caused by all known subtypes of HBV in adults ages 18 and older. The company said Heplisav-B is the only two-dose HBV vaccine approved...
23:46 , Nov 9, 2017 |  BC Extra  |  Company News

FDA approves Dynavax's HBV vaccine

Dynavax Technologies Corp. (NASDAQ:DVAX) gained $3 (15%) to $23.05 in after-hours trading Thursday after FDA approved Heplisav-B to prevent infection caused by all known subtypes of HBV in adults ages 18 and older. The company...